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Background-—Health system strengthening is needed to improve delivery of secondary prophylaxis against rheumatic heart
disease.
Methods and Results-—We undertook a stepped-wedge, randomized trial in northern Australia. Five pairs of Indigenous community
clinics entered the study at 3-month steps. Study phases comprised a 12 month baseline phase, 3 month transition phase, 12 month
intensive phase and a 3- to 12-monthmaintenance phase. Clinics received amulticomponent intervention supporting activities to improve
penicillin delivery, aligned with the chronic care model, with continuous quality-improvement feedback on adherence. The primary
outcome was the proportion receiving ≥80% of scheduled penicillin injections. Secondary outcomes included “days at risk” of acute
rheumatic fever recurrence related to late penicillin andacute rheumatic fever recurrence rates. Overall, 304 patients requiringprophylaxis
were eligible. The proportion receiving ≥80% of scheduled injections during baseline was 141 of 304 (46%)—higher than anticipated. No
effect attributable to the study was evident: in the intensive phase, 126 of 304 (41%) received ≥80% of scheduled injections (odds ratio
compared with baseline: 0.78; 95% confidence interval, 0.54–1.11). There was modest improvement in the maintenance phase among
high-adhering patients (43% received ≥90% of injections versus 30% [baseline] and 28% [intensive], P<0.001). Also, the proportion of days
at risk in the whole cohort decreased in the maintenance phase (0.28 versus 0.32 [baseline] and 0.34 [intensive], P=0.001). Acute
rheumatic fever recurrence rates did not differ between study sites during the intensive phase and the whole jurisdiction (3.0 versus 3.5
recurrences per 100 patient-years, P=0.65).
Conclusions-—This strategy did not improve adherence to rheumatic heart disease secondary prophylaxis within the study time
frame. Longer term primary care strengthening strategies are needed.
Clinical Trial Registration-—URL: www.anzctr.org.au. Unique identifier: ACTRN12613000223730. ( J Am Heart Assoc. 2018;7:
e009308. DOI: 10.1161/JAHA.118.009308.)
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R heumatic heart disease (RHD), which develops as acomplication of acute rheumatic fever (ARF), is an important cause of morbidity and mortality in areas ofsocioeconomic deprivation globally.1,2 ARF is an abnormal
From the Menzies School of Health Research, Darwin, Northern Territory, Australia (A.P.R., A.G.M., B.J.C., V.J.); Charles Darwin University, Darwin, Northern Territory,
Australia (A.P.R., J.L.d.D., B.J.C.); Royal Darwin Hospital, Darwin, Northern Territory, Australia (A.P.R., B.J.C.); National Health and Medical Research Council Clinical
Trials Centre, University of Sydney, New South Wales, Australia (A.K.); Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia (C.R.,
J.R.C.); Princess Margaret Hospital for Children, Perth, Western Australia, Australia (J.R.C.); Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.P.M.);
University of Sydney, University Centre for Rural Health, Lismore, New South Wales, Australia (R.S.B.); Medical School, Australian National University, Australian Capital
Territory, Canberra, Australia (V.J.); Perth Children’s Hospital, Perth, Western Australia, Australia (J.R.C.).
Accompanying Tables S1, S2 and Figures S1 through S4 are available at http://jaha.ahajournals.org/content/7/14/e009308/DC1/embed/inline-supplementary-
material-1.pdf
Correspondence to: Anna P. Ralph, BMedSci[Hons], MPH, MBBS, DTMH, FRACP, PhD, Royal Darwin Hospital Campus, John Matthews Building (Building 58),
Rocklands Drive, Casuarina, Northern Territory 0810, Australia. E-mail: anna.ralph@menzies.edu.au
Received March 28, 2018; accepted June 5, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.118.009308 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on September 4, 2018
immunological response that occurs in susceptible hosts after
infection with group A streptococcus. In recognition of the
high morbidity and mortality burden caused by RHD, the
World Health Assembly adopted a resolution on RHD in May
2018 acknowledging the need for a comprehensive approach
to the prevention and control of the disease in endemic
countries. In the Indigenous population living in Australia’s
Northern Territory (NT), very high rates are observed: Among
5- to 14-year-old Indigenous children, the annual incidence of
ARF is 250 per 100 0003 and prevalence of RHD is up to
1500 per 100 000.4 RHD accounts for one of the greatest
differential disease rates between Indigenous and non-
Indigenous Australians,2 with Indigenous people 55 times
more likely to die from ARF or RHD.5 Cumulative cardiac
valvular damage from recurrent ARF leads to RHD. The overall
incidence of progression to RHD has been estimated recently
in our setting at 51.9% within 10 years after initial ARF.6
The most effective strategy to prevent ARF recurrences
and RHD progression is secondary prevention with
intramuscular long-acting benzathine penicillin G (BPG) injec-
tions every 4 weeks for a minimum 10 years after the last
ARF episode or until age 21, whichever occurs later.7
Continued prophylaxis to age 35 is recommended for
moderate RHD and to age 40 or lifelong for severe RHD,
especially in those requiring valve surgery.7 Challenges to
delivery of this regimen in remote Australian settings are
similar to those in many resource-poor populations globally
with the highest RHD burdens: high turnover and limited ARF
knowledge among healthcare staff; young and mobile
patients; pain of injections; and cultural factors leading to
different concepts of disease causation and treatment, along
with barriers to acceptance of Western medicine.8–10 The
proportion of patients in the NT in 2009 with ARF/RHD
achieving ≥80% of scheduled injections—the current Aus-
tralian benchmark for acceptable adherence7—was only
25%.11
We hypothesized that barriers to adherence would be
amenable to a health system intervention, based on elements
of the chronic care model (CCM)12 and using continuous
quality improvement (CQI) processes. The CCM for chronic
disease management incorporates 6 domains: health sys-
tems, delivery system design, decision support, clinical
information systems, self-management support, and commu-
nity linkages.12 These domains have high applicability to ARF/
RHD management. Interventions based on the CCM have the
potential to improve health outcomes.13,14 CQI approaches
use data proactively to motivate healthcare providers and
clinic managers to work toward improved targets. Application
of CQI has shown promise previously in the NT, with
implementation at 6 remote clinics leading to improvements
in some ARF/RHD outcomes.11 Health systems improve-
ments providing a “comprehensive care program” or combin-
ing education strategies with development of a register have
also been associated with ARF rate reductions in the United
States, Cuba, and the Caribbean.15–17 Nevertheless, method-
ological aspects of previous studies may limit the inferences
that can be drawn and extended to other settings.
We aimed to test whether a health systems intervention
engaging staff and patients at primary care clinics and the
regional RHD control program would improve delivery of
secondary prophylaxis for people with ARF and/or RHD. A
comprehensive mixed-methods evaluation done in parallel is
reported separately.18
Methods
Study Design
The RHDSP (Rheumatic Heart Disease Secondary Prophylaxis)
trial was a stepped-wedge, pragmatic, community, random-
ized trial with an open cohort design using mixed-methods
Clinical Perspective
What Is New?
• This multicomponent intervention at 10 remote Australian
Aboriginal clinics did not improve adherence to penicillin
among people with rheumatic fever or rheumatic heart
disease during a 12-month time frame, demonstrating the
substantial challenges to effective adherence support.
• Adherence was already improving overall in this setting; the
proportion receiving the nominated target of ≥80% of
scheduled injections was 46% at baseline, more than double
the previously published rate.
• Although improvement in the primary outcome was not
seen, patients who were already well engaged experienced
benefit during longer term follow-up.
• Longer interventions are needed, with more community
linkages, to achieve better adherence in this cross-cultural
context.
What Are the Clinical Implications?
• Secondary prophylaxis with penicillin is a highly effective
strategy to reduce progression from acute rheumatic fever
to rheumatic heart disease or from milder to more severe
forms of rheumatic heart disease, but strategies to support
adherence that are culturally appropriate and age appropri-
ate are needed.
• The challenges identified in this study make a compelling
case for investment in better preventive strategies at
primordial and primary levels.
• More patient-centered approaches within culturally compe-
tent health systems are a priority to achieve improved
outcomes for individuals living with rheumatic heart disease.
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evaluation. The study protocol was published previously.19 A
stepped-wedge trial is an alternative to a parallel cluster trial
design. After an initial period of no intervention, clusters (in
this case, pairs of communities) commence the intervention
at regular intervals (steps). Data are collected throughout,
allowing for the staggered intervention phases to be com-
pared with the baseline phases. The study was conducted in
Australia’s NT, in Indigenous communities, most of them in
very remote locations. Each has a single primary healthcare
center (clinic) servicing the community. Patients can be
mobile between communities but have a “primary clinic”
nominated (the clinic takes responsibility for patients’ treat-
ment, where the majority of their injections are delivered).
Approval was provided by the Human Research Ethics
Committee of the NT Department of Health and Menzies
School of Health Research (no. 2012-1756) and the Central
Australian Human Research Ethics Committee (no. 2013-
126). The trial was registered with the Australian New
Zealand Clinical Trials Registry: ACTRN 12613000223730.
The anonymized quantitative data and study materials will
be been made available on request to the authors for
purposes of reproducing the results or replicating the
procedure.
Participants
The unit of participation was healthcare centers, which were
eligible if they had ≥10 patients with ARF and/or RHD
requiring secondary prophylaxis and provided written
informed consent from the health center manager or
management board. Of note, in Australia, the term Indigenous
includes Aboriginal and Torres Strait Islander peoples; in our
study, all Indigenous people were Aboriginal Australians,
reflecting the demographics of the Indigenous NT population.
Consent from individuals was not required for quantitative
data collection; these data were routinely collected and
reported to the regional RHD Control Program. For qualitative
data collection, healthcare providers at participating clinics,
patients with ARF and/or RHD, and key stakeholders involved
in ARF care were invited to participate in interviews. Informed
consent for interviews was sought by project officers or a
qualitative researcher using written and verbal materials, with
information provided in an Australian Indigenous language, if
appropriate. For patients aged <15 years, consent was
sought from a parent or guardian and assent was requested
from the interviewee.
Randomization and Masking
Clusters in the stepped-wedge study comprised pairs of
health centers that entered at 3-month steps in random order.
The random allocation code was computer generated centrally
at the National Health and Medical Research Council Clinical
Trials Center. No components of the intervention were subject
to masking.
Procedures
Study phases comprised (1) baseline data collection
(12 months), (2) transition phase with commencement of
intensive phase activities but data excluded from outcome
analyses (3 months); (3) intensive implementation phase
(12 months), (4) maintenance implementation phase (3–
15 months, depending on each site’s start date; Figure 1).19
The intervention comprised a set of activities (“action
plans”) aligned under the themes of the CCM and developed
and implemented by health centers. Implementation was
supported by project officers via monthly face-to-face meet-
ings during the transition and intensive phase (ie, 15 times)
and every 3 months during the maintenance phase. CQI
activities comprised meetings between the staff of partici-
pating heath centers and project officers to review quarterly
adherence rates, presented as simple graphics, and discus-
sion of progress against action plans. If clinics were unable to
be visited because of closure, such as for a funeral or flooding,
project officers sought a meeting by telephone. All efforts
were made to ensure that exposure to the intervention,
measured as the number of clinic support visits conducted
face-to-face or by telephone, was homogeneous across sites
and in accordance with the stepped-wedge design.
Outcomes
The a priori primary outcome was proportion of patients
receiving ≥80% of their scheduled BPG injections over the 12-
month intensive phase compared with the baseline phase.
Secondary outcome measures were proportion of scheduled
injections that a patient received; average number of “days at
risk” of ARF due to late penicillin dosing (median number
>28 days between scheduled injections)20 in a 12-month
period; proportion of patients in other adherence strata (90–
100%, 50–79% and <50% of scheduled BPG injections);
recurrence rate and proportion of ARF episodes that were
recurrences compared with nonparticipating communities and
the whole jurisdiction; impact of the intervention on RHD
patients’ experience of care, including their perception and
understanding of the disease and its management; improve-
ment in delivery of other services for RHD patients; and effect
of the program on delivery of other routine services.
Data
Adherence data (penicillin injection dosing with date and
location of administration) were obtained from the NT RHD
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Control Program Register. A subset of these data was
checked for accuracy against primary clinic data, and
corrected if required, for the whole study period, as reported
elsewhere.21 The NT Aboriginal Health Key Performance
Indicator (AHKPI) data—an aggregated, deidentified data set
—were used to measure the secondary outcome of impact of
the intervention on other services. Prespecified indicators
selected were AHKPI 1.4.1: Fully Immunized Children; AHKPI
1.7: Chronic Disease Management Plan for diabetic patients;
AHKPI 1.11: Adult Health Check, aged ≥55 years; AHKPI
1.12: Pap Smear Tests in the previous 2 years.
“One21Seventy” RHD audits19,22 were used to measure
aspects of ARF/RHD care other than penicillin adherence,
such as whether a timely echocardiogram and cardiologist
review had been undertaken. These audits are an initiative
of the National Center for Quality Improvement in Indige-
nous Primary Health Care and provide deidentified data.
Community and clinic characteristics were derived from the
Australian Bureau of Statistics and project officer reports.
Staff stability was defined as the average number of
months that a single person was in the RHD nurse
coordinator role at each healthcare center during the
transition and intensive phases; a higher score indicates
greater staffing stability.
Qualitative data collection comprised semistructured inter-
views with ARF/RHD patients, clinic staff, and key
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Figure 1. Stepped-wedge study design.
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stakeholders and project officer reports summarizing each
episode of contact with a healthcare center. A nested focused
ethnographic study (description of cultural behavior focused
on ARF and RHD) was conducted at 4 sites, investigating
patients’ perspectives on their condition.
Project Evaluation
A program theory was developed using the 6 themes of the
CCM as the framework.19 We hypothesized that a cascade of
potential outcomes arising from these activities would occur,
leading to increased adherence and thus reduction in ARF
recurrence rates. Effectiveness of implementation of the
project was measured according to fidelity, dose, and reach.
Fidelity included whether participating healthcare centers
developed action plans and implemented activities as
planned; dose comprised the number and nature of scheduled
contacts achieved between clinics and project officers (face-
to-face visits as intended or conducted by phone); reach of
the intervention comprised the number and quality of action
items and comprehensiveness across the CCM themes.
Evaluation findings are reported separately.18
Statistical Analyses
Using a stepped-wedge design with a 3-month period for each
step, with enough communities to provide at least 30
participants at each step and taking into account within-
cluster correlation, 300 patients were required to provide 90%
power and a 2-sided significance level of 5% to detect an
increase from 20% to 40% of participants receiving ≥80% of
their scheduled penicillin injections.
The intervention was implemented at the level of the
community health center, but measured by its impact on
ARF/RHD patients and health center staff. All patients with
ARF and/or RHD whose primary clinic was participating in the
study were included. In an a priori plan taking account of
population mobility, analyses were restricted to those who,
during the baseline and intensive phases of the study, resided
in a study site for at least 75% of the time (≥9 of 12 months
during each phase of quantitative data collection) and
required penicillin prophylaxis for ≥12 months during each
of the baseline and intensive phases of the study. To avoid
potential adherence rates of >100% and counting multiple
needles administered within a short time frame, adherence
calculations excluded doses given within 14 days of each
other; however, all doses were retained in calculations of days
at risk.
Analyses of adherence were based on observations for
each participant in each time period and used generalized
linear mixed models to account for the correlation within a
person over time and between people within the same clinic.
The primary analysis included only the baseline and intensive
phases. When the maintenance phase was included in the
analysis, the results showed the maintenance phase com-
pared with the baseline and intensive phases, with a test for
trend over the 3 time points. Binary outcomes included
whether a patient received ≥80%, ≥90%, <50%, and 50% to
79% of scheduled BPG injections over the 12-month intensive
phase. Days at risk of ARF recurrence were presented in 2
ways: number of days >28 days (or >21 for those prescribed
21-day regimens) that occurred between scheduled injections
in a 12-month period or proportion (days at risk divided by
number of days that penicillin was intended). Days at risk
were Poisson distributed, and proportion of days at risk was
normally distributed and analyzed using a generalized linear
mixed model. Results are presented as odds ratios, rate
ratios, or absolute differences and 95% confidence intervals.
Patients had to be included in both baseline and intensive
phases to be included in the analysis. Comparison of ARF
recurrence rates was undertaken using MedCalc software. All
other analyses were undertaken in SAS 9.3 (SAS Institute).
The impacts of the study on delivery of other services for
RHD patients and on other routine clinic activities were
assessed using One21Seventy and AHKPI data, respectively.
For several reasons, graphical descriptions rather than
statistical tests were undertaken for these outcome mea-
sures: the time frames for aggregated data sets did not
exactly align with the stepped-wedge design, not all sites
undertook One21Seventy audits, and One21Seventy data are
deidentified so could not be used in individual patient-level
adherence analyses.
Healthcare provider interview transcripts and project
officer reports were subjected to deductive coding by 3
researchers in NVivo qualitative data analysis software (v10,
2012; QSR International Pty Ltd). Codes were determined a
priori according to established criteria. Interpretation of
findings was made in consultation with the project staff and
other study investigators. Patient interview transcripts were
analyzed using an exploratory inductive approach.
Role of the Funding Source
The trial was funded by the Australian National Health and
Medical Research Council and Wesfarmers Center for Vacci-
nes and Infectious Diseases at Telethon Kids Institute. The
funders had no role in the study design, data collection,
analysis, interpretation, or writing of this report.
Results
We approached 30 health centers about participation. Ten
agreed to participate, providing 402 participants at study
commencement. Factors associated with nonparticipation
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included a sense of “research fatigue” and concern about
added work burden the study might generate. The Template
for Intervention Description and Replication checklist23 is
provided in Table S1. Ninety-eight participants were excluded
for having <9 of 12 months of available adherence data at any
participating study site during the intensive phase (Figure 2),
leaving 304 for analysis. Some patients moved between study
sites, and some left the study (died, no longer required
prophylaxis, moved to a nonparticipating site), accounting for
slight differences in numbers available at each site during
different study phases. Key study dates are shown in
Figure 1. Health center characteristics are shown in Table 1.
Chief attributes were that most communities were classified
as very remote (eg, in 1 instance, >7-hour drive on unsealed
roads from the nearest regional center), with small popula-
tions but high numbers of individuals per household and low
incomes. Four clinics were run by community-controlled
health boards and 6 by the Government Department of
Health. Staff turnover was high: During the 15-month period
of data collection from start of transition to end of intensive
phase, the number of healthcare providers at each study site
holding the portfolio of RHD coordinator ranged from 2 to 8
(Figure S1). Only 1 site provided an outreach (community-
based) service.
Adherence Outcomes
Primary and secondary outcomes are presented in Table 2.
The proportion of patients receiving ≥80% of scheduled BPG
injections was 141 of 304 (46%) in the baseline phase and
126 of 304 (41%) during the intensive phase (odds ratio: 0.78;
95% confidence interval [CI], 0.54–1.11]). During the mainte-
nance phase, this proportion increased to 148 of 297 (50%;
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odds ratio compared with baseline: 1.18 [95% CI, 0.81–1.72];
odds ratio compared with intensive phase: 1.55 [95% CI,
1.07–2.26]; Table 2). The proportion of patients receiving
≥90% of scheduled BPG injections was 92 of 304 (30%) during
the baseline phase. An increase occurred in this adherence
measure in the maintenance phase to 128 of 297 (43%),
compared with the intensive phase (odds ratio: 2.43; 95% CI,
1.63–3.62). The number of days at risk (Table 3) was not
significantly different during the intensive phase (median:
98 days; interquartile range: 56–177) compared with baseline
(median: 86 days; interquartile range: 49–162; rate ratio:
0.95 [95% CI, 0.89–1.02]). However, the proportion of days at
risk decreased in the maintenance phase (0.28 versus 0.32
[baseline] and 0.34 [intensive], P=0.001). ARF recurrence
rates did not differ between study sites during the intensive
phase and the whole jurisdiction (3.0 versus 3.5 recurrences
per 100 patient-years, P=0.65). There was no interaction
between the prespecified subgroups (age, sex, site) and
change in adherence.
There was a large difference between sites in adherence
(Table 4 and Figure 3): the proportion of patients receiving
≥80% of injections at baseline ranged from 7% to 89%
(P<0.001). Differences in adherence also occurred between
age groups (Table 4), being best in children ≤10 years and
worst in the group aged 21 to 40 years (P<0.001). Adherence
did not differ between male and female patients.
ARF Recurrences
Recurrence rates of definite or probable ARF diagnosed
using the Jones criteria during intensive phase were
compared between the 10 participating sites and the
whole NT during the relevant period (March 1, 2014, to
February 29, 2016). During the intensive phase, 9 definite
or probable ARF recurrences occurred at participating sites
in individuals identified as needing secondary prophylaxis
(3.0 recurrences per 100 patient-years), compared with 3.5
recurrences per 100 patient-years in the whole jurisdiction
(P=0.66).
Determinants of Adherence and of Change in
Adherence
No associations were seen between adherence and objec-
tively quantifiable characteristics of health centers, commu-
nities, or project activities including patient numbers per site,
staff turnover, participation or not in One21Seventy audits,
socioeconomic indicators, numbers of action items com-
pleted, number of study visits achieved, or governance
structure (Table 4, Figure S2). Multivariable analyses using
clinic-level characteristics as predictors of response could not
be undertaken because outcomes were analyzed on a per-
patient basis, and analysis on a per-clinic level would have
been inappropriate because of having only 10 outcome
variable data points but many clinic-level predictor variables,
potential correlation between the predictor variables, and no
replication of measures. These data are described in Tables 1
and 2. However, there were specific case examples illustrating
the complex interplay of factors that might influence adher-
ence. One site achieving high adherence during the intensive
phase (93% of patients getting ≥80% of scheduled injections;
Figure 3, siteD) had community-controlled governance, stable
staffing, a small ARF patient caseload (<30 individuals), very
remote location, One21Seventy audits, 13 of 15 scheduled
visits completed, and implementation of 10 action items
during the intensive phase. In contrast, a site with low
adherence during the intensive phase (33% of getting ≥80%;
Figure 3, site I) had higher staff turnover, undertook only 5
action items, had 9 of 15 study visits, and did not participate
in One21Seventy audits, yet, like site D, also had community-
controlled governance, a small caseload, and very remote
location. Such factors are explored in detail in the project
evaluation.18
Project Implementation
Regarding fidelity to the protocol, all participating sites
successfully developed action plans to address penicillin
delivery for ARF/RHD patients (Table S1); however, 3 sites
experienced delays (Figure 1 and Table 2). Examples of
action plan items are provided in Table S2—for example,
changing electronic patient recall systems to ensure early
reminders of penicillin doses and triaging ARF/RHD
patients to high priority to avoid long waiting times for
injection delivery. The dose of the intervention ranged
from 7 of 15 face-to-face visits at one site up to 14 of 15
at another (Table 2). The reach of the intervention varied
with numbers of completed action items ranging from 1 to
13 (Table 2, Figure S2Q). Project officer report data
indicated that activities continued into the maintenance
phase.
Impact of the Intervention on RHD Patients’
Experience of Care
The focused ethnographic study exploring patients’ experi-
ences of care at sites A, C, D, and G involved 35 ARF/RHD
patients (aged 7–35 years) and 37 family members or
Aboriginal key informants. Main themes are presented in
summary in this article; detailed qualitative findings are
presented elsewhere.18 A key theme that emerged was that
patient knowledge of ARF/RHD and the reason for regular
injections was very limited. Patients had many unanswered
questions about their conditions that they felt powerless to
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ask. This was compounded by communication difficulties
given the need to operate in a second language (English) in
health services. Patients generally did not recount a
discernible impact from the intervention. Some did note
value in being able to access injections outside the clinic
via outreach services and receiving reminder text messages
via mobile telephone from clinics. Others perceived that the
only change over time affecting their care was staff
turnover.
Impact of the Study on Other Clinic Activities
NT AHKPI data from the participating sites are shown in
Figure S3. Adherence to ARF treatment according to the
AHKPI data set showed close association with our study data
set, indicating validity of the AHKPI data (Figure S3E). The
proportions of individuals receiving guideline-compliant care
in the nominated categories (immunization, chronic disease
management, adult health check, Pap smear) showed no
overall association with the study’s primary outcome and no
suggestion of an impact of the study on the other clinic
activities. Clinic performance in other indicators generally
exceeded performance in ARF prophylaxis, and interclinic
variability in performance was greatest for ARF prophylaxis.
RHD file audit results (One21Seventy audits) were examined
to look for associations between penicillin adherence and
other aspects of ARF/RHD care. Results at the 5 participating
sites that undertook audits during baseline and intensive
phases are shown in Figure S4. The figure suggests that sites
achieving the best adherence results also did well in ensuring
that people had timely echocardiography, dental review, and
influenza vaccination. However, associations with adherence
were not apparent at all sites (eg, site B), and no association
was evident between response to the study intervention and
performance in other aspects of ARF/RHD care.
Discussion
In this first rigorous randomized controlled trial to test the
impact of a health systems intervention on delivery of RHD
secondary prophylaxis, no significant increase in adherence
was achieved. Improvement in documented adherence was
already evident at the outset of this study: double (46%) the
proportion of patients were receiving ≥80% of scheduled
injections compared with the previous estimate (23%).24 The
intervention was unable to achieve a further incremental
improvement over this background rise. Twelve months may
have been insufficient to detect a true effect, given the complex
intervention we implemented. There was improvement during
the maintenance phase in the proportion of patients receiving
≥90% of scheduled injections. This suggests, first, that patients
already engaging well gained the most from the intervention,
whereas those who were struggling did not benefit—they need
to be reached by other means. Second, it suggests that the type
of intervention implemented, which used CQI processes, may
take longer to have effect than we anticipated when devising
the primary outcome measure. This is supported by findings
from a study using CQI to improve the delivery of diabetes
mellitus care in Australian Indigenous communities: Longer
duration of participation in CQI audit cycles, up to 6 years, was
an important determinant of improved outcomes.25
Reasons for the overall increase in documented adherence
in the NT may include the now-widespread local practice (days
at risk approach) of recalling patients for their 28-day injection
from day 21 onward to avoid late delivery.20 This practice has
been gradually implemented since 2014 and was recom-
mended at all our participating sites to avoid days at risk
between penicillin doses. In addition, there have been ongoing
efforts to strengthen primary health care throughout the NT,
including CQI programs, for several years before this project
commenced, and that may have contributed to the trends in
improvement before baseline—this may have limited our ability
to show an impact of our intervention. Furthermore, a spurious
increase in adherence because of higher quality data may have
occurred. Indeed, the data cleaning we undertook resulted in an
8-percentage-point increase in calculated adherence.21
Age and site were significant predictors of adherence.
Reassuringly, adherence was best in children, who have the
highest risk of ARF recurrence. Given methodological con-
straints—having only 10 participating sites for comparison, but
with diverse characteristics—we were unable to identify
individual community, clinic, or project implementation factors
in statistical analyses that significantly predicted adherence or
response to the study intervention. It appeared that a complex
Health Care Center
Figure 3. Proportion of patients receiving ≥80% of sched-
uled benzathine penicillin doses during baseline, intensive, and
maintenance phases at all sites and according to individual
study site.
DOI: 10.1161/JAHA.118.009308 Journal of the American Heart Association 12
RHDSP Trial Ralph et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on September 4, 2018
interplay of factors at high-performing sites contributed to their
ability to deliver care more effectively. Chief among these was
the presence of stable staffing provided by culturally competent
individuals working within well-functioning clinics. Previous
research in our setting has identified that staff who are able to
identify with patients and healthcare centers that value quality
improvement initiatives and are successful in developing
effective community linkages respond more effectively to CQI
initiatives.26 Objectively measuring the “culture” of a clinic,
healthcare provider quality and health service cultural compe-
tence, is difficult—although research is under way to measure
institutional cultural competence more effectively.27 Clinic
governance differed between sites, with some under local
Aboriginal community control and others being government-
run. Governance structure was not found to be associated with
outcomes in this study (Table 4, Figure S2N).
A key factor that we believe impeded project success was
staffing challenges, including high turnover (Table 4)—a well-
recognized problem in our setting28,29 Solutions to rural
health workforce shortages and turnover have been identified,
including increased training and workplace support for
Aboriginal people; strategies to develop professional devel-
opment opportunities, peer support, and community connect-
edness for nonlocal staff; and placement of students to
promote rural and remote career choices.30 Findings from our
study suggest that greater effort is needed in implementing
such strategies. At one site (A), the RHD portfolio was
overseen by 8 different nurses during a 15-month period.
Although we sought to implement measures that would be
durable in the face of staff turnover, project officers noted
failures of handover, and patients noted the difficulty of
engaging with a clinic where staff were very frequently new
and unfamiliar. Despite these context-specific findings, similar
factors may operate internationally in settings with high RHD
burdens. ARF and RHD occur at high rates among Indigenous
populations of Canada, New Zealand, South America, and
globally in resource-limited settings1; many of our findings
could be generalizable to such settings.
We used the CCM to guide and categorize the activities that
clinics undertook to improve delivery of penicillin injections.
Clinics found some aspects of chronic disease management
easier to implement than others—the majority of implemented
action items involved changing clinic-based systems such as
software-embedded recall systems or undertaking staff train-
ing. Far more challenging was the ability to establish effective
community linkages or to provide self-management support.
Among the 10 clinics, only 4 action items in the self-
management support domain were undertaken (Table S2).
Self-management has many definitions but is understood to be
an approach to chronic disease management that acknowl-
edges patients as active participants in their treatment and
encourages them to make informed decisions about care and
engage in healthy behaviors.31,32 Self-management is poorly
named for our setting because Australian Aboriginal culture
universally values group identity. A term such as “community
group-based care” would be more appropriate. Major invest-
ment is now required to conceptualize, develop, and implement
effective “self-management” strategies in our setting.
The AHKPI data attest to the added challenges of the
delivery of RHD prophylaxis compared with other routine
services, which were more likely to meet or approach targets
(Figure S4). The RHD medical record audit data (One21Se-
venty audits) indicated some associations—high-performing
clinics did well across most aspects of ARF/RHD care—but
the project activities seeking to improve adherence did not
have apparent spill-over effects, neither improving nor
detracting from a focus in other domains.
A chief limitation of the study is the short time frame.
Stepped-wedge designs have advantages over traditional
cluster randomized community trials,19 and this model was
appropriate to use for this study. A disadvantage, however, is
the added time requirement: We collected data for >3.5 years,
but this provided only a 12-month intensive intervention period.
As per the stepped design, maintenance-phase data were
available for only 3 months from some sites, so results from
this phase need to be interpreted with caution. There was
heterogeneity of the intervention at different participating sites;
however, we ensured it was as comparable and structured as
possible while also allowing site-specific tailoring to address
differing clinic needs and to allow a sense of ownership of the
project by the healthcare providers implementing the activities.
Accounting for patient movements between sites was statis-
tically complex; patients were not necessarily living at study
sites for the whole period. We analyzed patient data according
to their nominated primary clinic, but injections were also
delivered at other sites (primary clinics supposedly take
responsibility for notifying traveling patients and destination
clinics that a penicillin dose is due). In addition, to reduce the
impact of patient movements, we restricted analyses to
patients who were at a study site for at least 75% of the
intensive phase. Female patients were underrepresented in this
study; they comprise 62% of individuals on the NT RHD
register but only 35% in our study. Because adherence did not
differ between male and female patients in our study, this is
unlikely to have affected the study findings.
Conclusion
Secondary prevention is the cornerstone of international ARF
and RHD control, but effectiveness is limited by suboptimal
adherence. Our findings indicate the critical importance of
improving engagement between healthcare services and Abo-
riginal patients. The barriers to this improvement need to be
addressed by engaging the highest levels of health system
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governance, using innovative staff education and retention
measures and ensuring cultural security within healthcare
environments. A wide range of other creative strategies need to
be explored, such as use of social media, incentives, peer-
support groups, and consideration of community support
personnel employed to assist Aboriginal people in navigating
the healthcare system. The ongoing challenges in delivery of
secondary prophylaxis make a compelling case to broaden the
scope of ARF prevention activities, with particular emphasis on
primordial and primary prevention both among individuals with
existing ARF or RHD and among whole communities. Research
now under way is engaging communities to address high
streptococcal transmission in households and communities to
provide community-led solutions to reducing the strikingly high
rates of RHD.
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Table S1: TIDieR (Template for Intervention Description and Replication) checklist1 
Item Description 
Name A health systems intervention to improve delivery of secondary prophylaxis for people with acute rheumatic fever (ARF) and 
rheumatic heart disease (RHD). 
Why Adherence to secondary prophylaxis (SP) is sub-optimal. There are lost opportunities for prevention of ARF recurrences, 
which drive the progression to RHD. RHD has high morbidity and mortality. Factors important in the delivery of secondary 
prophylaxis include robust patient recall systems and care of patients which is culturally appropriate and engaging. An 
intervention targeted at health centres to improve these processes could increase adherence, and thereby, reduce ARF 
recurrences and progression to RHD.   
What  Documents: Partnership Agreement between clinic management (health centre manager or management board) and study 
investigator; Participant information forms and consent sheets provided for interviews.  
Materials: Printed reports and verbal discussion of health centre progress for continuous quality improvement cycles, based 
on 3-monthly summaries of their centre’s adherence data, and progress with Action Plan items; study newsletter highlighting 
ideas and progress at all participatign sites; clinician and patient educational resources e.g. 
www.rhdaustralia.org.au/resources, www.rhdaustralia.org.au/health-worker-modules, www.rhdaustralia.org.au/clinician-
modules 
Procedures: collaborative development of Action Plan by healthcare providers and project team, to identify activities to 
improve SP delivery under the 6 themes of the Chronic Care Model. See Supplementary Table 3.  
Interviews: interviews were undertaken to ascertain healthcare provider and client views on delivery and receipt of penicillin 
secondary prophylaxis, and to seek opinions from key stakeholders on health system structures to support ARF care.  
Who provided Health centre staff (doctors, nurses, Aboriginal Health Practitioners, managers) supported by two project officers (registered 
nurses) supporting five health centres each.  
Logistical support provided by Project Manager and Project Coordinator (administration staff). 
Clinical and other support and overall project supervision provided by study investigators (clinician researchers). 
How Face to face meetings: project officers visited communities regularly.   
Support between visits: telephone and email. 
Quarterly study newsletter distributed by email and provided in hard copy during site visits. 
Where Health centres at ten communities in the Northern Territory of Australia. These were widely spaced geographically - up to 
2000 km apart. 
When and how 
much 
Baseline phase: 12 months of data collection without project officer visits 
Transition (wash in) phase: 3 months during which intensive phase activities were commenced but quantiative data 
collectino was not undertaken 
Intensive phase: 12 months of data collection with monthly scheduled face-to-face project officer visits 
Maintenance phase: 3-12 months of data collection with monthly telephone contact and 3-monthly face-to-face project 
officer visits 
Tailoring Each participating health centre was invited to create their own ‘Action plan’ to improve delivery of rheumatic fever 
prophylaxis. Project officers provided ideas to include in the Action Plan, ensured that actions were appropriate, determined 
that actions could be categorized under a theme of the Chronic Care Model and provided motivation and facilitation to 
complete action items. 
Modifications If face-to-face visits were unable to be achieved, these were replaced by telephone ‘meetings’.  
If clinics were unable to commence the study on the date allocated by the randomization schedule, all milestones for that site 
were adjusted accordingly. 
How well Planned: intervention adherence and fidelity were captured in regular project officer reports. Strategies to maintain fidelity 
included weekly staff meetings and quarterly chief investigator meetings to manage issues arising, regular checking of project 
progress against the protocol, and negotiation with clinic management when issues such as lack of site access arose. 
Actual: ‘Dose’ of intervention delivery (number of face-to-face visits) differed between sites as shown in the manuscript. 
Reasons for missed site visits included: health centre requested no visit due to competing priorities; health centre inaccessible 
due to flooding; health centre not operating routinely due to large community funeral or other event. 
Degree of engagement with healthcare providers and health centre management varied between sites. 
The number, quality and relevance of core action items completed by clinics varied between sites. 
1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald
H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW and Michie S. Better reporting of
interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ.
2014;348:g1687.
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Table S2. Examples of action plan items. 
 
Chronic Care 
Model theme 
Examples of activities undertaken at participating healthcare centres Number of completed core action items by end of intensive phase 
 A B C D E F G H I J TOTAL 
Clinical 
information 
systems 
- Establish a list of all ARF secondary prophylaxis (SP) patients in the electronic 
medical record 
- Set up an alert in the electronic medical record to flag SP patients  
- Regularly cross-check and update the clinic list against the Control Program register 
list 
- Change patient recall from 28 to 21 days to ensure patient has time to attend for needle 
by day 28  
- Determine where patients prefer to receive their injection (e.g. clinic, home, school) 
and document this in a consistent place in the electronic medical record 
- Develop regular data sharing process between adjacent communities for patients who 
live for period of time in both communities 
- Develop a system for handing the RHD Portfolio over to future RHD coordinators  
1 6 8 6 0 2 0 3 1 2 29 
Community 
linkages 
- Consult with the local school about the feasibility of injection administration at the 
school 
- Liaise with community elders about a strategy for delivering injections during 
ceremonial business 
- Provide information on ARF/RHD to a Women’s community group (‘Women's 
Yarning Circle’) 
- Incorporate RHD health promotion into Heart Week promotional activities 
0 0 0 1 0 1 0 1 1 0 4 
Decision Support - Ensure all relevant staff have undertaken the RHD educational online modules e.g. 
include these in the staff orientation package and provide time for existing staff to do 
these 
- Invite the NT RHD Control Program staff to visit the community to provide education 
to staff on RHD care 
- Include a discussion of SP data as a standing agenda item for clinical staff meetings  
- Ensure that all staff are familiar with pain minimisation techniques for administering 
intramuscular injections 
0 3 1 2 2 0 3 2 2 1 16 
Delivery System 
Design 
- Ensure a nurse is assigned to the RHD Coordinator position and clarify the position 
description 
- Ensure that triage and other processes for SP patients are fast tracked  
- Build a new cubicle in the waiting room to fast track injection delivery 
- Ensure all SP patients have a current penicillin prescription 
- Identify strategies for administering injections to children during the school e.g. 
determine where children will be spending the school holidays and liaise with the 
relevant community clinic 
- Implement the use of vibrating ice packs (‘Buzzy BeeTM’) for pain minimisation; 
document in the electronic medical record who wishes to have this device used 
- Allocate an RHD program day which is not Monday or Friday to avoid clinic closures 
and public holidays  
0 3 1 1 1 0 0 2 1 1 10 
Health Systems - Discuss RHD at the clinic board meeting and explain the significance of the disease 
and the importance of SP. Get input from board members on ways to strengthen 
delivery of care.  
- Clarify the role of the NT RHD Control Program team (what they can do to support the 
clinic) 
0 1 1 0 0 0 0 0 0 0 2 
Self Management 
Support 
- Encourage staff to undertake online Self Management Support training  0 0 1 0 1 0 0 2 0 0 4 
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- Introduce ways to remind patients of when their injection is due: reminder cards/ 
phone calls/ text message / calendar in phone / wall calendar 
- Develop a smartphone application (app) to provide patients with reminders about 
injections; Educate patients about the app 
- Design hand-held reminder cards in appropriate Aboriginal language 
- Distribute wall calendars to patients 
- Distribute adherence certificates to patients  
- Obtain feedback from patients on which reminder method they prefer 
 
ARF: acute rheumatic fever; injection:  refers to injections of benzathine penicillin G; NT: Northern Territory; SP: secondary prophylaxis; RHD: rheumatic heart disease 
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Figure S1. RHD coordinator staff turnover during the 15-month period of data collection from start of transition 
to end of intensive phase of the study. 
 
 
At each of the 10 participating sites, the nurse (or in one instance, an Aboriginal Health Practitioner) assigned the RHD 
Coordinator role is signified by a number and corresponding colour. At some sites during all or part of the 15-month 
period, two individuals were assigned the role. In some sites an individual left and then later returned to the role.  
 
 
 
Month A C D F G I J
1 1 1 2 1 1 1 1 1 2 1 1
2 2 1 2 1 1 2 1 1 2 1 1
3 3 1 2 1 1 2 1 1 2 1 1
4 2 1 2 1 1 2 1 1 2 1 1
5 2 1 2 1 1 2 1 1 3 1 1
6 2 1 2 1 1 *** 2 1 4 1 2
7 2 1 2 1 1 2,3 2 1 4 1 2
8 4 1 2 2 1 3 2 1 4 *** 2
9 2 1 2 2 1 4 5 3 2 1 4 *** 3
10 2 1 2 2 1 4 5 3 2 1 4 2 3
11 5 1 *** 2 1 4 5 3 2 1 4 2 3
12 5 1 *** 2 1 4 5 3 2 1 4 2 3
13 6 1 *** 2 1 4 5 4 2 1 4 2 ***
14 7 3 *** 2 1 4 5 5 2 1 2 2 4
15 8 3 *** 1 2 6 *** *** 2 1 2 2 4
Total: 8 2 2 5 2 2 4
*** : no RHD coordinator
6 4
B
3
2
2
3
3
3
E H
1
1
2
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Figure S2. Association between adherence (percentage of patients receiving ≥80% of scheduled injections during 
intensive phase) and clinic characteristics.  No associations were found to be statistically significant at p<0.05  
 
 
A. Adherence by RHD nurse coordinator 
turnover stability score. Higher value 
indicates higher turnover. 
 
 
  
B. Adherence by geographical location of clinic 
in the Top End or Central area of the 
Northern Territory 
 
C. Adherence by Accessibility/remoteness index 
of Australia (ARIA) score 
 
D. Adherence by Australian statistical 
geography standard-remoteness area score  
 
E. Adherence by household crowding: number 
of people per house 
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F. Adherence by household crowding: number 
of people per bed  
 
G. Adherence by number of patients in the 
community needing ARF prophylaxis 
 
 
H. Adherence by age of patients in the 
community needing ARF prophylaxis 
 
I. Adherence by proportion of patients in the 
community needing ARF prophylaxis who 
are male 
 
 
J. Adherence by community population 
 
K. Adherence by availability of alcohol in the 
community (dry = alcohol not legally 
obtainable) 
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L. Adherence by participation of the clinic in 
‘One21Seventy’ audits in the intensive phase 
 
 
N. Adherence by type of governance of clinics 
(Government Department of Health (DOH) or 
Community Controlled (CC)) 
 
O. Adherence by index of relative social 
economic disadvantage (lower score means 
less advantaged) 
 
 
P. Adherence by median weekly household 
income 
 
Q. Adherence by number of action items 
acheived 
 
R. Adherence by provision of outreach 
(community-based) services for patients 
requiring ARF prophylaxis during intensive 
phase 
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Figure S3. Associations between Aboriginal Health Key Performance Indicators between 2013 and 2016, and adherence as 
calculated for this study during the intensive phase of the study. 
 
 
A. Proportion of children fully immunised  
 
 
B. Proportion of people with diabetes and chronic heart 
disease with a management plan in place 
 
C. Proportion of adults aged >55 years receiving an annual 
health check 
D. Proportion of women in required age range having a pap 
smear every two years 
E. Proportion of patients with ARF receiving ≥80% of 
scheduled BPG injections as documented in the AHKPI  
 
F. Adherence at each site during the intensive phase of the 
study, as a comparison with AHKPIs shown in A-E 
 
Colored bars show the percentage of all patients at the clinic who had the variable of interest documented. Note, access to AHKPI 
data was not provided by Site I. Black bars shows the primary outcome i.e. proportion of patients receiving ≥80% of scheduled 
BPG injections during the intensive phase. The intensive phase occurred at different time intervals depending on the random order 
in which sites entered the study.   
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Figure S4. Results of rheumatic heart disease audit results (‘One21Seventy’ audits of medical files) in relation to 
adherence to secondary prophylaxis.  
 
 
A. Documentation of echocardiogram in the last 3 years 
 
B. Documentation of dental review in the last 2 years 
 
C. Documentation of receipt of influenza vaccine in the 
last 2 years 
 
D. Documentation of receipt of adequate pneumococcal 
vaccine dosing 
 
E. Documentation of any doctor review in the last 2 
years 
 
F. Documentation of specialist doctor review in the last 
2 years 
 
Colored bars show the percentage of audited individuals who had the variable of interest documented. Black dots and lines show 
adherence at that site during baseline and intensive phase. Five of the participating sites undertook audits during baseline and 
intensive phases.  
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